NFKB1 and osteoporosis: TBMS I has potential development value in the treatment of osteoporosis; it can inhibit NF-κB signaling pathway to reduce the production of osteoclasts, so as to protect against bone damaging diseases such as osteoporosis caused by type 2 diabetes (Yang et al., 2019; Yang et al., 2020).